Q2 2025 Earnings Call Transcript August 11, 2025 BioCardia, Inc. beats earnings expectations. Reported EPS is $-0.4, ...

Q2 2025 Earnings Call Transcript August 12, 2025 Lineage Cell Therapeutics, Inc. misses on earnings expectations. Reported ...

FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Strong ...

Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial ...

Kula approaches impact investing as a critical avenue to build the future of worldwide communities, starting with the ...

Key Points Net product revenue (GAAP) rose 11% to $24.2 million, Net product revenue exceeded analyst estimates by $1.063 million (GAAP), rising 11% to $24.2 million. GAAP net loss per share widened ...

ZUSDURITM (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent lo ...

Operating expenses decreased sharply compared to Q2 2024, supporting a cash runway into the second quarter of 2026. - Dose expansion enrollment was completed for the lead product in its main clinical ...

With grit and discernment, Mark Hanna is the leader of Hanna Farms, a row crop farm in north-central Iowa. What sets him ...

On June 12, 2025, the U.S. Food and Drug Administration (FDA) approved ZUSDURI (formerly UGN-102), the first and only FDA-approved medication for adults with recurrent LG-IR-NMIBC.

The best portable grills deliver all the smoky, seared-up goodness of a full-size barbecue in a smaller, more travel-friendly ...